Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of cytochromes P450 3A422 and 3A53 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.

PloS one - 1 Jan 2022

Elalem Elbatool G, Jelani Musharraf, Khedr Alaa, Ahmad Aftab, Alaama Tareef Y, Alaama Mohamed Nabeel, Al-Kreathy Huda M, Damanhouri Zoheir A

Abstract excerpt

BACKGROUNDS: Inter-individual variability in response to statin was mainly due to genetic differences. This study aimed to investigate the association of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) single nucleotide polymorphism (SNP) with response to simvastatin in hypercholesterolemia patients conducted at King Abdulaziz University hospital (KAUH) in Jeddah, Saudi Arabia. PATIENTS AND METHODS: A total of 274...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL
Share to Cytochrome P-450 CYP3A
Share to Genotype
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors
Share to Hypercholesterolemia
Share to Polymorphism, Single Nucleotide
Share to Simvastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 35839255
DOI: 10.1371/journal.pone.0260824
PMCID: PMC9286239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.PMID 35839255Read ↗

CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Semantic proximity Read ↗

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.Semantic proximity Read ↗

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.Semantic proximity Read ↗

Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.Semantic proximity Read ↗

Statins personalized.Semantic proximity Read ↗

Pharmacogenetics of statins treatment: Efficacy and safetySemantic proximity Read ↗

The pharmacogenomics of statins.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.Semantic proximity Read ↗

Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.